Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): Results from patients with ≥12 months of treatment in JAVELIN Bladder 100

被引：0
|
作者：
Aragon-Ching, Jeanny B. [1 ]
Grivas, Petros [2 ]
Loriot, Yohann [3 ]
Bellmunt, Joaquim [4 ]
Pook, David W. [5 ]
Wang, Jing [6 ]
Michelon, Elisabete [7 ]
di Pietro, Alessandra [8 ]
Powles, Thomas [9 ]
Sridhar, Srikala S. [10 ]
机构：
[1] Inova Schar Canc Inst, Fairfax, VA USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Paris Saclay, INSERMU981, Gustave Roussy, Villejuif, France
[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA USA
[5] Monash Hlth, Dept Oncol, Melbourne, Vic, Australia
[6] Pfizer, Cambridge, MA USA
[7] Pfizer, New York, NY USA
[8] Pfizer Srl, Milan, Italy
[9] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Barts Canc Inst, London, England
[10] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228
引用
收藏
页码：138 / 139
页数：2
相关论文
共 50 条
  • [1] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
    Aragon-Ching, J. B.
    Grivas, P.
    Loriot, Y.
    Bellmunt, J.
    Wang, J.
    Michelon, E.
    di Pietro, A.
    Powles, T. B.
    Sridhar, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
  • [2] Avelumab first-line maintenance for advanced or metastatic urothelial carcinoma: analysis from JAVELIN Bladder 100 trial
    Madiraju, Srigita
    Petros, Firas G.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (07) : 1327 - 1328
  • [3] Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Climent, Miguel Angel
    Sridhar, Srikala S.
    Powles, Thomas
    Cislo, Paul
    Michelon, Elisabete
    Di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
    Gupta, S.
    Climent Duran, M. A.
    Sridhar, S.
    Powles, T. B.
    Bellmunt, J.
    Tyroller, K.
    Guenther, S.
    di Pietro, A.
    Grivas, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1207 - S1207
  • [5] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1 L chemotherapy
    Valderrama, Begona P.
    Powles, Thomas
    Sridhar, Srikala S.
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora N.
    Pook, David W.
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert J.
    di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 139 - 139
  • [6] Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
    Sridhar, Srikala S.
    Powles, Thomas
    Duran, Miguel A. Climent
    Park, Se Hoon
    Massari, Francesco
    Thiery-Vuillemin, Antoine
    Valderrama, Begona P.
    Ullen, Anders
    Tsuchiya, Norihiko
    Aragon-Ching, Jeanny B.
    Gupta, Shilpa
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Wang, Jing
    Laliberte, Robert J.
    di Pietro, Alessandra
    Costa, Nuno
    Grivas, Petros
    Sternberg, Cora N.
    Loriot, Yohann
    EUROPEAN UROLOGY, 2024, 85 (02) : 154 - 163
  • [7] Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
    Powles, T. B.
    Sridhar, S.
    Bellmunt, J.
    Sternberg, C.
    Grivas, P.
    Hunter, E.
    Dezfouli, M.
    Salter, M.
    Powell, R.
    Dring, A.
    Green, J.
    Akoulitchev, A.
    Amezquita, R.
    Ching, K.
    Pu, J.
    Deng, S.
    di Pietro, A.
    Davis, C. B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1442 - S1442
  • [8] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes
    Loriot, Yohann
    Gupta, Shilpa
    Powles, Thomas
    Grivas, Petros
    Petrylak, Daniel P.
    Tyroller, Karin
    Jacob, Natalia
    Hoffman, Jason
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
    Perez-Valderrama, Begona
    Powles, Thomas
    Sridhar, Srikala S.
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora N.
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL
    Powles, Thomas
    Petrylak, Daniel P.
    Park, Se Hoon
    Sridhar, Srikala S.
    Caserta, Claudia
    Thiery-Vuillemin, Antoine
    Lee, Hyo Jin
    Bellmunt, Joaquim
    Yamamoto, Yoshiaki
    Aragon-Ching, Jeanny B.
    Huang, Bo
    Ching, Keith
    Davis, Craig
    di Pietro, Alessandra
    Loriot, Yohann
    Grivas, Petros
    JOURNAL OF UROLOGY, 2021, 206 : E765 - E766
12345